Join
Live feed
·
PRReleasevia Quantisnow
Viracta Therapeutics Inc. logo

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

ByQuantisnow·Wall Street's wire, on your screen.
VIRX· Viracta Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VIRX (Viracta Therapeutics Inc.) and more on Quantisnow.